Innocan Pharma Announces Details of Proposed Share Consolidation

HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2025 /CNW/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CNSX:INNO.CN) (FSE:IP4) (OTC-BB:INNPF) is pleased to announce that further to its press release dated July 23, 2025, it will be consolidating all of its issued and outstanding common shares ("Common Shares") on the basis of one (1) post-consolidation Common Share for each 65 pre-consolidation Common Shares (the "Share Consolidation"). The Share Consolidation represents another step towards the completion of a proposed public offering of units (the "Units") in the United States as set out in its registration statement on Form F-1 that has been publicly filed with the U.S. Securities and Exchange Commission (the "SEC") and the listing of the Common Shares on the NASDAQ Capital Market ("NASDAQ").